Lenvatinib Mesylate E7080 Tyrosine Kinase Inhibitor Cas 857890-39-2

Lenvatinib, also known as E7080, is a synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase with potential antineoplastic activity. E7080 blocks VEGFR2 activation by VEGF, resulting in inhibition of the VEGF receptor signal transduction pathway, decreased vascular endothelial cell migration and proliferation, and vascular endothelial cell apoptosis.

Lenvatinib Mesylate (E7080) is a synthetic, orally available tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR1-3), fibroblast growth factor receptor (FGFR1-4), platelet-derived growth factor receptor α (PDGFRα), stem cell factor receptor (Kit (c-Kit)), and rearranged during transfection (RET (c-RET)). Lenvatinib Mesylate has potential antineoplastic activity.

FGFR Inhibitors Related Products:

Infigratinib; PD173074; AZD4547; Danusertib; Brivanib alaninate; Pemigatinib; Lenvatinib; Nintedanib esylate; BLU9931; SKLB610; Roblitinib

[1] Matsui J, et al. Int J Cancer. 2008, 122(3), 664-671.

[2] Ana M Molina, et al. Cancer Chemother Pharmacol . 2014 Jan